cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Olema Pharmaceuticals Inc
3 own
10 watching
Current Price
$4.65
$-0.2
(-4.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
186.39M
52-Week High
52-Week High
6.08
52-Week Low
52-Week Low
2
Average Volume
Average Volume
0.22M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization186.39M
icon52-Week High6.08
icon52-Week Low2
iconAverage Volume0.22M
iconDividend Yield--
iconP/E Ratio--
What does the Olema Pharmaceuticals Inc do?
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More
How much money does Olema Pharmaceuticals Inc make?
News & Events about Olema Pharmaceuticals Inc.
Globe Newswire
1month ago
SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema, Olema Oncology, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on ...
Globe Newswire
2 months ago
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Companys complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment ...
Globe Newswire
3 months ago
OP-1250 continues to demonstrate favorable tolerability, high drug exposure, and strong anti-tumor activity in preliminary Phase 1/2 study results presented at the 34th EORTC-NCI-AACR SymposiumInitial clinical data for OP-1250 in combination with CDK 4/6 inhibitor palbociclib expected in the fourth ...
Zolmax
8 months ago
ProShare Advisors LLC acquired a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Rating) during the fourth quarter, Holdings Channel reports. The firm acquired 11,173 shares of the companys stock, valued at approximately $105,000. A number of other hedge funds and ...
Ticker Report
8 months ago
ProShare Advisors LLC acquired a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The firm acquired 11,173 shares of the company...
Frequently Asked Questions
Frequently Asked Questions
What is Olema Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Olema Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Olema Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Olema Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Olema Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Olema Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Olema Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Olema Pharmaceuticals Inc?
plus_minus_icon
What percentage is Olema Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Olema Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.65
$-0.2
(-4.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00